Trial intelligence / Profile preview

Foster versus Symbicort for small airway function in COPD

2010-022895-30Phase 3Terminated

Sponsor
Chiesi Farmaceutici S.p.A.
Start
May 2011
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of beclometasone dipropionate + formoterol and budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline to end of treatment in post-dose residual volume. Started May 2011; status: terminated.

02

Drugs

beclometasone dipropionate + formoterolbudesonide
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on 2010-022895-30.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022895-30.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call